Migration Potential of Cancel Cells
Determination of the Migration Potential in Breast and Lung Cancer Cells in presence of antimigratory therapeutic agent.
Marco Brudik and Paloma Aranzazu Godinez Melgoza
Medical and Pharmaceutical Biotechnology Program, University of Applied Sciences IMC FH Krems.
Abstract. The new trends on research points to study the process of tomour-cell invasion and metastasis for developing and testing of anti-migratory agents. The present study develops a quantitative determination of the cancer cell’s migratory potential by Cell transendothelial migration assay. The cancer cell’s migratory potential may be affected by exposure to antimigratory agents such as Gefitinib. The Gefitinib inhibits the cellular progression and migration by blocking the EGF receptors. Our studies reveled the effect on the migration rate in breast and lung cancer with exposure to Gefitinib, consequently the migration rate decrease 20%.
Introduction
Cancer is a major health problem for humankind, and the approaches to its treatment have clear limitations. Cancer kills patients essentially because of the migratory nature of its cells. Indeed, it is now well established that cell migration plays pivotal roles in cancer cell scattering, tissue invasion and metastasis, these processes are essentially responsible for the dismal prognoses of a majority of cancer patients. Thus, as an alternative to treatments designed only to kill cancer cells, researchers must today focus on developing the means to reduce or even to prevent the migration of these cells14. * Tumor-cell invasion and migration.
The process of tumour-cell invasion and metastasis is conventionally understood as the migration of individual cells that detach from the primary tumour, enter lymphatic vessels or the bloodstream and seed in distant organs. During the early stages of carcinogenesis, a disorganization of epithelial cell–cell junctional complexes may occur during the EMT process This may result in the disruption of
Marco Brudik and Paloma Aranzazu Godinez Melgoza
Medical and Pharmaceutical Biotechnology Program, University of Applied Sciences IMC FH Krems.
Abstract. The new trends on research points to study the process of tomour-cell invasion and metastasis for developing and testing of anti-migratory agents. The present study develops a quantitative determination of the cancer cell’s migratory potential by Cell transendothelial migration assay. The cancer cell’s migratory potential may be affected by exposure to antimigratory agents such as Gefitinib. The Gefitinib inhibits the cellular progression and migration by blocking the EGF receptors. Our studies reveled the effect on the migration rate in breast and lung cancer with exposure to Gefitinib, consequently the migration rate decrease 20%.
Introduction
Cancer is a major health problem for humankind, and the approaches to its treatment have clear limitations. Cancer kills patients essentially because of the migratory nature of its cells. Indeed, it is now well established that cell migration plays pivotal roles in cancer cell scattering, tissue invasion and metastasis, these processes are essentially responsible for the dismal prognoses of a majority of cancer patients. Thus, as an alternative to treatments designed only to kill cancer cells, researchers must today focus on developing the means to reduce or even to prevent the migration of these cells14. * Tumor-cell invasion and migration.
The process of tumour-cell invasion and metastasis is conventionally understood as the migration of individual cells that detach from the primary tumour, enter lymphatic vessels or the bloodstream and seed in distant organs. During the early stages of carcinogenesis, a disorganization of epithelial cell–cell junctional complexes may occur during the EMT process This may result in the disruption of
References: 3. Lauffenburger, D.A. ¬ Horwitz, A. F. Cell Migration: a physically integrate molecular process. Cel 84, 359-369 (1996) 4 10. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3, 401–410 (2003). 11. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15–18 (2002). 19. Munagala, Radha, Farrukh Aqil, and Ramesh C. Gupta. "Abstract." National Center for Biotechnology Information. U.S. National Library of Medicine, 30 Oct. 0005.